{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:59:54Z","timestamp":1785729594130,"version":"3.56.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014751","name":"Neuraxpharm","doi-asserted-by":"publisher","award":["Funding of the writing of the manuscript"],"award-info":[{"award-number":["Funding of the writing of the manuscript"]}],"id":[{"id":"10.13039\/501100014751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40261-025-01493-0","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:53:31Z","timestamp":1761656011000},"page":"923-933","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Midazolam Oromucosal Solution for the Management of Prolonged Convulsive Seizures in Adult Outpatients: Addressing Unmet Needs in Europe"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-275X","authenticated-orcid":false,"given":"Mar","family":"Carre\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Ha","family":"Kim-Wisskirchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Forcadell Ferr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Mu\u00f1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Valiante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"1493_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/epd2.20243","author":"JE Pina-Garza","year":"2024","unstructured":"Pina-Garza JE, Chez M, Cloyd J, Hirsch LJ, Kalviainen R, Klein P, et al. Outpatient management of prolonged seizures and seizure clusters to prevent progression to a higher-level emergency: consensus recommendations of an expert working group. Epileptic Disord. 2024. https:\/\/doi.org\/10.1002\/epd2.20243.","journal-title":"Epileptic Disord"},{"issue":"6","key":"1493_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","volume":"14","author":"JP Betjemann","year":"2015","unstructured":"Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14(6):615\u201324. https:\/\/doi.org\/10.1016\/S1474-4422(15)00042-3.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1493_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/epi.14515","volume":"59","author":"C Sculier","year":"2018","unstructured":"Sculier C, Gainza-Lein M, Sanchez Fernandez I, Loddenkemper T. Long-term outcomes of status epilepticus: a critical assessment. Epilepsia. 2018;59(2):155\u201369. https:\/\/doi.org\/10.1111\/epi.14515.","journal-title":"Epilepsia"},{"issue":"10","key":"1493_CR4","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","volume":"56","author":"E Trinka","year":"2015","unstructured":"Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus\u2014report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515\u201323. https:\/\/doi.org\/10.1111\/epi.13121.","journal-title":"Epilepsia"},{"key":"1493_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.seizure.2016.11.001","volume":"44","author":"E Trinka","year":"2017","unstructured":"Trinka E, Kalviainen R. 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure. 2017;44:65\u201373. https:\/\/doi.org\/10.1016\/j.seizure.2016.11.001.","journal-title":"Seizure"},{"issue":"9","key":"1493_CR6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","volume":"36","author":"R Kienitz","year":"2022","unstructured":"Kienitz R, Kay L, Beuchat I, Gelhard S, von Brauchitsch S, Mann C, et al. Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability. CNS Drugs. 2022;36(9):951\u201375. https:\/\/doi.org\/10.1007\/s40263-022-00940-2.","journal-title":"CNS Drugs"},{"issue":"8","key":"1493_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.seizure.2013.04.015","volume":"22","author":"LJ Greenfield Jr","year":"2013","unstructured":"Greenfield LJ Jr. Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure. 2013;22(8):589\u2013600. https:\/\/doi.org\/10.1016\/j.seizure.2013.04.015.","journal-title":"Seizure"},{"issue":"3","key":"1493_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s13311-023-01359-3","volume":"20","author":"GL Krauss","year":"2023","unstructured":"Krauss GL, Elizebath R, Mwendaweli N. Seizure rescue therapies: comparing approved and commonly used benzodiazepine formulations. Neurotherapeutics. 2023;20(3):758\u201366. https:\/\/doi.org\/10.1007\/s13311-023-01359-3.","journal-title":"Neurotherapeutics"},{"key":"1493_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081754","author":"S Almohaish","year":"2021","unstructured":"Almohaish S, Sandler M, Brophy GM. Time is brain: acute control of repetitive seizures and status epilepticus using alternative routes of administration of benzodiazepines. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10081754.","journal-title":"J Clin Med"},{"key":"1493_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.seizure.2024.04.005","volume":"118","author":"M Maltseva","year":"2024","unstructured":"Maltseva M, Rosenow F, von Podewils F, Habermehl L, Langenbruch L, Bierhansl L, et al. Predictors for and use of rescue medication in adults with epilepsy: a multicentre cross-sectional study from Germany. Seizure. 2024;118:58\u201364. https:\/\/doi.org\/10.1016\/j.seizure.2024.04.005.","journal-title":"Seizure"},{"issue":"10","key":"1493_CR11","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1007\/s10072-021-05468-9","volume":"42","author":"D Samanta","year":"2021","unstructured":"Samanta D. Rescue therapies for seizure emergencies: current and future landscape. Neurol Sci. 2021;42(10):4017\u201327. https:\/\/doi.org\/10.1007\/s10072-021-05468-9.","journal-title":"Neurol Sci"},{"issue":"8","key":"1493_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40263-018-0544-2","volume":"32","author":"J Kadel","year":"2018","unstructured":"Kadel J, Bauer S, Hermsen AM, Immisch I, Kay L, Klein KM, et al. Use of emergency medication in adult patients with epilepsy: a multicentre cohort study from Germany. CNS Drugs. 2018;32(8):771\u201381. https:\/\/doi.org\/10.1007\/s40263-018-0544-2.","journal-title":"CNS Drugs"},{"key":"1493_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108242","volume":"123","author":"R Shankar","year":"2021","unstructured":"Shankar R, Goodwin M, Toland J, Boyle A, Grant A, Pearson J, et al. Oro-mucosal midazolam maleate: use and effectiveness in adults with epilepsy in the UK. Epilepsy Behav. 2021;123:108242. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108242.","journal-title":"Epilepsy Behav"},{"key":"1493_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108180","volume":"122","author":"P Tittensor","year":"2021","unstructured":"Tittensor P, Tittensor S, Chisanga E, Bagary M, Jory C, Shankar R. UK framework for basic epilepsy training and oromucosal midazolam administration. Epilepsy Behav. 2021;122:108180. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108180.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1493_CR15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/epi.16847","volume":"62","author":"J Cloyd","year":"2021","unstructured":"Cloyd J, Haut S, Carrazana E, Rabinowicz AL. Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters. Epilepsia. 2021;62(4):846\u201356. https:\/\/doi.org\/10.1111\/epi.16847.","journal-title":"Epilepsia"},{"issue":"1","key":"1493_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.17925\/USN.2024.20.1.2","volume":"20","author":"S Goodman","year":"2024","unstructured":"Goodman S, Chan G, Gunawardane N, Kuzniecky R. Acute management of seizure clusters and prolonged seizures: a review of rescue therapies. touchREVIEWS in Neurology. 2024;20(1):4\u20139.","journal-title":"touchREVIEWS in Neurology"},{"issue":"6","key":"1493_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/s1525-5050(02)00559-0","volume":"3","author":"IW Tatum","year":"2002","unstructured":"Tatum IW. Adult patient perceptions of emergency rectal medications for refractory seizures. Epilepsy Behav. 2002;3(6):535\u20138. https:\/\/doi.org\/10.1016\/s1525-5050(02)00559-0.","journal-title":"Epilepsy Behav"},{"issue":"2","key":"1493_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-0404.2010.01474.x","volume":"124","author":"KO Nakken","year":"2011","unstructured":"Nakken KO, Lossius MI. Buccal midazolam or rectal diazepam for treatment of residential adult patients with serial seizures or status epilepticus. Acta Neurol Scand. 2011;124(2):99\u2013103. https:\/\/doi.org\/10.1111\/j.1600-0404.2010.01474.x.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"1493_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/17425247.2025.2470224","volume":"22","author":"F Brako","year":"2025","unstructured":"Brako F, Boateng J. Transmucosal drug delivery: prospects, challenges, advances, and future directions. Expert Opin Drug Deliv. 2025;22(4):525\u201353. https:\/\/doi.org\/10.1080\/17425247.2025.2470224.","journal-title":"Expert Opin Drug Deliv"},{"key":"1493_CR20","unstructured":"Electronic Medicines Compendium. Diazepam Desitin 5 mg Rectal solution. 2019. https:\/\/www.medicines.org.uk\/emc\/product\/2997\/smpc\/print. Accessed 6 Mar 2025."},{"key":"1493_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106675","volume":"102","author":"F Minicucci","year":"2020","unstructured":"Minicucci F, Ferlisi M, Brigo F, Mecarelli O, Meletti S, Aguglia U, et al. Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy. Epilepsy Behav. 2020;102:106675. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106675.","journal-title":"Epilepsy Behav"},{"issue":"10","key":"1493_CR22","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s00115-020-01036-2","volume":"92","author":"F Rosenow","year":"2021","unstructured":"Rosenow F, Weber J, Deutsche Gesellschaft fur N, Osterreichische Gesellschaft fur N. S2k guidelines: status epilepticus in adulthood: guidelines of the German Society for Neurology [in German]. Nervenarzt. 2021;92(10):1002\u201330. https:\/\/doi.org\/10.1007\/s00115-020-01036-2.","journal-title":"Nervenarzt"},{"issue":"2","key":"1493_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.nrl.2013.12.020","volume":"31","author":"JM Mercade Cerda","year":"2016","unstructured":"Mercade Cerda JM, Toledo Argani M, Mauri Llerda JA, Lopez Gonzalez FJ, Salas Puig X, Sancho Rieger J. The Spanish Neurological Society official clinical practice guidelines in epilepsy. Neurologia. 2016;31(2):121\u20139. https:\/\/doi.org\/10.1016\/j.nrl.2013.12.020.","journal-title":"Neurologia"},{"key":"1493_CR24","unstructured":"National Institute for Health and Care Excellence. Epilepsies in children, young people and adults. 2022. https:\/\/www.nice.org.uk\/guidance\/ng217\/chapter\/7-Treating-status-epilepticus-repeated-or-cluster-seizures-and-prolonged-seizures#prolonged-seizures. Accessed 11 Jul 2024."},{"key":"1493_CR25","unstructured":"Electronic Medicines Compendium. Buccolam 10 mg oromucosal solution. 2024. https:\/\/www.medicines.org.uk\/emc\/product7460\/smpc\/print. Accessed 17 Mar 2025."},{"key":"1493_CR26","unstructured":"European Medicines Agency. Nasolam and associated names\u2014referral. 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/nasolam-and-associated-names. Accessed 15 Jul 2024."},{"issue":"9","key":"1493_CR27","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1111\/epi.15159","volume":"60","author":"K Detyniecki","year":"2019","unstructured":"Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng TC, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60(9):1797\u2013808. https:\/\/doi.org\/10.1111\/epi.15159.","journal-title":"Epilepsia"},{"issue":"3","key":"1493_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/pharmaceutics11030113","volume":"11","author":"M Ghadiri","year":"2019","unstructured":"Ghadiri M, Young PM, Traini D. Strategies to enhance drug absorption via nasal and pulmonary routes. Pharmaceutics. 2019;11(3):113. https:\/\/doi.org\/10.3390\/pharmaceutics11030113.","journal-title":"Pharmaceutics"},{"key":"1493_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.seizure.2024.01.003","volume":"115","author":"N Chmielewska","year":"2024","unstructured":"Chmielewska N, Szyndler J. Intranasal administration of antiseizure medications in chronic and emergency treatment: hopes and challenges. Seizure. 2024;115:62\u20137. https:\/\/doi.org\/10.1016\/j.seizure.2024.01.003.","journal-title":"Seizure"},{"key":"1493_CR30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40005-020-00482-z","volume":"50","author":"M Gao","year":"2020","unstructured":"Gao M, Shen X, Mao S. Factors influencing drug deposition in the nasal cavity upon delivery via nasal sprays. J Pharm Investig. 2020;50:251\u20139.","journal-title":"J Pharm Investig"},{"issue":"5","key":"1493_CR31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ejpn.2010.05.009","volume":"14","author":"MR Ashrafi","year":"2010","unstructured":"Ashrafi MR, Khosroshahi N, Karimi P, Malamiri RA, Bavarian B, Zarch AV, et al. Efficacy and usability of buccal midazolam in controlling acute prolonged convulsive seizures in children. Eur J Paediatr Neurol. 2010;14(5):434\u20138. https:\/\/doi.org\/10.1016\/j.ejpn.2010.05.009.","journal-title":"Eur J Paediatr Neurol"},{"issue":"9","key":"1493_CR32","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1177\/000992280504400904","volume":"44","author":"S Baysun","year":"2005","unstructured":"Baysun S, Aydin OF, Atmaca E, Gurer YK. A comparison of buccal midazolam and rectal diazepam for the acute treatment of seizures. Clin Pediatr (Phila). 2005;44(9):771\u20136. https:\/\/doi.org\/10.1177\/000992280504400904.","journal-title":"Clin Pediatr (Phila)"},{"issue":"4","key":"1493_CR33","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2165\/11209320-000000000-00000","volume":"14","author":"KP Garnock-Jones","year":"2012","unstructured":"Garnock-Jones KP. Oromucosal midazolam: a review of its use in pediatric patients with prolonged acute convulsive seizures. Paediatr Drugs. 2012;14(4):251\u201361. https:\/\/doi.org\/10.2165\/11209320-000000000-00000.","journal-title":"Paediatr Drugs"},{"issue":"9481","key":"1493_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0140-6736(05)66909-7","volume":"366","author":"J McIntyre","year":"2005","unstructured":"McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Phillips B, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366(9481):205\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(05)66909-7.","journal-title":"Lancet"},{"issue":"11","key":"1493_CR35","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1097\/PEC.0000000000001114","volume":"35","author":"R Moretti","year":"2019","unstructured":"Moretti R, Julliand S, Rinaldi VE, Titomanlio L. Buccal midazolam compared with rectal diazepam reduces seizure duration in children in the outpatient setting. Pediatr Emerg Care. 2019;35(11):760\u20134. https:\/\/doi.org\/10.1097\/PEC.0000000000001114.","journal-title":"Pediatr Emerg Care"},{"issue":"1","key":"1493_CR36","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1542\/peds.2007-0930","volume":"121","author":"A Mpimbaza","year":"2008","unstructured":"Mpimbaza A, Ndeezi G, Staedke S, Rosenthal PJ, Byarugaba J. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics. 2008;121(1):e58-64. https:\/\/doi.org\/10.1542\/peds.2007-0930.","journal-title":"Pediatrics"},{"issue":"9153","key":"1493_CR37","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0140-6736(98)06425-3","volume":"353","author":"RC Scott","year":"1999","unstructured":"Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353(9153):623\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(98)06425-3.","journal-title":"Lancet"},{"issue":"10","key":"1493_CR38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2165\/11209350-000000000-00000","volume":"26","author":"LJ Scott","year":"2012","unstructured":"Scott LJ, Lyseng-Williamson KA, Garnock-Jones KP. Oromucosal midazolam: a guide to its use in paediatric patients with prolonged acute convulsive seizures. CNS Drugs. 2012;26(10):893\u20137. https:\/\/doi.org\/10.2165\/11209350-000000000-00000.","journal-title":"CNS Drugs"},{"key":"1493_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109914","volume":"158","author":"S Okazaki","year":"2024","unstructured":"Okazaki S, Kumagai T, Nishiuma S, Iwasaki K, Yamamoto K, Kokubo K, et al. Emergency management of pediatric epileptic seizures in non-hospital settings in Japan. Epilepsy Behav. 2024;158:109914. https:\/\/doi.org\/10.1016\/j.yebeh.2024.109914.","journal-title":"Epilepsy Behav"},{"key":"1493_CR40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pediatrneurol.2020.03.011","volume":"109","author":"K Alansari","year":"2020","unstructured":"Alansari K, Barkat M, Mohamed AH, Al Jawala SA, Othman SA. Intramuscular versus buccal midazolam for pediatric seizures: a randomized double-blinded trial. Pediatr Neurol. 2020;109:28\u201334. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2020.03.011.","journal-title":"Pediatr Neurol"},{"issue":"10","key":"1493_CR41","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.braindev.2008.11.006","volume":"31","author":"B Talukdar","year":"2009","unstructured":"Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial. Brain Dev. 2009;31(10):744\u20139. https:\/\/doi.org\/10.1016\/j.braindev.2008.11.006.","journal-title":"Brain Dev"},{"issue":"3","key":"1493_CR42","first-page":"303","volume":"22","author":"SH Tonekaboni","year":"2012","unstructured":"Tonekaboni SH, Shamsabadi FM, Anvari SS, Mazrooei A, Ghofrani M. A comparison of buccal midazolam and intravenous diazepam for the acute treatment of seizures in children. Iran J Pediatr. 2012;22(3):303\u20138.","journal-title":"Iran J Pediatr"},{"issue":"8","key":"1493_CR43","first-page":"411","volume":"21","author":"R Melendez","year":"2006","unstructured":"Melendez R, Batista D, Font D, Bausa T, Hijano A, Rocha A, et al. Prolonged convulsions treated with buccal midazolam in a setting of mentally retarded patients with refractory epilepsy [in Spanish]. Neurologia. 2006;21(8):411\u20133.","journal-title":"Neurologia"},{"issue":"6","key":"1493_CR44","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2165\/00003495-198428060-00002","volume":"28","author":"JW Dundee","year":"1984","unstructured":"Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam. A review of its pharmacological properties and therapeutic use. Drugs. 1984;28(6):519\u201343. https:\/\/doi.org\/10.2165\/00003495-198428060-00002.","journal-title":"Drugs"},{"issue":"2","key":"1493_CR45","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40272-013-0009-5","volume":"15","author":"D Lee","year":"2013","unstructured":"Lee D, Gladwell D, Batty AJ, Brereton N, Tate E. The cost effectiveness of licensed oromucosal midazolam (Buccolam\u00ae) for the treatment of children experiencing acute epileptic seizures: an approach when trial evidence is limited. Paediatr Drugs. 2013;15(2):151\u201362. https:\/\/doi.org\/10.1007\/s40272-013-0009-5.","journal-title":"Paediatr Drugs"},{"key":"1493_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13561-014-0006-6","volume":"4","author":"DC Lee","year":"2014","unstructured":"Lee DC, Gladwell D, Hatswell AJ, Porter J, Brereton N, Tate E, et al. A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe. Health Econ Rev. 2014;4:6. https:\/\/doi.org\/10.1186\/s13561-014-0006-6.","journal-title":"Health Econ Rev"},{"issue":"11","key":"1493_CR47","doi-asserted-by":"crossref","first-page":"481","DOI":"10.33588\/rn.5811.2014057","volume":"58","author":"M Raspall-Chaure","year":"2014","unstructured":"Raspall-Chaure M, Martinez-Bermejo A, Sanchez-Carpintero R, Ruiz-Falco Rojas ML, Verdu-Perez A, Smeyers-Dura P, et al. Cost-effectiveness of buccal midazolam in the treatment of prolonged convulsive seizures in the outpatient setting in Spain [in Spanish]. Rev Neurol. 2014;58(11):481\u20136.","journal-title":"Rev Neurol"},{"issue":"1","key":"1493_CR48","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/ane.12814","volume":"137","author":"E Beghi","year":"2018","unstructured":"Beghi E, Capovilla G, Franzoni E, Minicucci F, Romeo A, Verrotti A, et al. Midazolam vs diazepam in prolonged seizures in children: a pharmacoeconomic approach. Acta Neurol Scand. 2018;137(1):24\u20138. https:\/\/doi.org\/10.1111\/ane.12814.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1493_CR49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s41669-019-0164-x","volume":"4","author":"C Ludwig","year":"2020","unstructured":"Ludwig C, Fisher L. Buccal midazolam solution for the management of prolonged acute convulsive seizures: a cost analysis. Pharmacoecon Open. 2020;4(1):171\u20139. https:\/\/doi.org\/10.1007\/s41669-019-0164-x.","journal-title":"Pharmacoecon Open"},{"issue":"3","key":"1493_CR50","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40272-018-0286-0","volume":"20","author":"A Arzimanoglou","year":"2018","unstructured":"Arzimanoglou A, D\u2019Cruz O, Nordli D, Shinnar S, Holmes GL, E. A review of the new antiepileptic drugs for focal-onset seizures in pediatrics: role of extrapolation. Paediatr Drugs. 2018;20(3):249\u201364. https:\/\/doi.org\/10.1007\/s40272-018-0286-0.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"1493_CR51","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","volume":"16","author":"T Glauser","year":"2016","unstructured":"Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48\u201361. https:\/\/doi.org\/10.5698\/1535-7597-16.1.48.","journal-title":"Epilepsy Curr"},{"issue":"10","key":"1493_CR52","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/epi.13859","volume":"58","author":"JM Pellock","year":"2017","unstructured":"Pellock JM, Arzimanoglou A, D\u2019Cruz O, Holmes GL, Nordli D, Shinnar S, et al. Extrapolating evidence of antiepileptic drug efficacy in adults to children >\/=2 years of age with focal seizures: the case for disease similarity. Epilepsia. 2017;58(10):1686\u201396. https:\/\/doi.org\/10.1111\/epi.13859.","journal-title":"Epilepsia"},{"issue":"4","key":"1493_CR53","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejpn.2019.05.002","volume":"23","author":"A Arzimanoglou","year":"2019","unstructured":"Arzimanoglou A, Kalilani L, Anamoo MA, Cooney M, Golembesky A, Taeter C, et al. Role of observational studies in supporting extrapolation of efficacy data from adults to children with epilepsy - A systematic review of the literature using lacosamide as an example. Eur J Paediatr Neurol. 2019;23(4):589\u2013603. https:\/\/doi.org\/10.1016\/j.ejpn.2019.05.002.","journal-title":"Eur J Paediatr Neurol"},{"key":"1493_CR54","unstructured":"L\u00f3pez Bermudo C, Carre\u00f1o M, Valiante C, Vozmediano V, Muniz P, Forcadell M, et al. Definition of adult posology of midazolam oromucosal solution for prolonged sizures based on a population pharmacokinetic model [abstract 383]. In: European epilepsy congress; 7\u201311 September 2024; Rome, Italy."},{"issue":"8968","key":"1493_CR55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/s0140-6736(95)91209-6","volume":"346","author":"TM Bauer","year":"1995","unstructured":"Bauer TM, Ritz R, Haberth\u00fcr C, Ha HR, Hunkeler W, Sleight AJ, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet. 1995;346(8968):145\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(95)91209-6.","journal-title":"Lancet"},{"issue":"6","key":"1493_CR56","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/clpt.1992.84","volume":"51","author":"JW Mandona","year":"1992","unstructured":"Mandona JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite \u03b1-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther. 1992;51(6):715\u201328. https:\/\/doi.org\/10.1038\/clpt.1992.84.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1493_CR57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1365-2125.1983.tb02272.x","volume":"16","author":"WH Ziegler","year":"1983","unstructured":"Ziegler WH, Schalch E, Leishman B, Eckert M. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. Br J Clin Pharmacol. 1983;16(1):63\u20139. https:\/\/doi.org\/10.1111\/j.1365-2125.1983.tb02272.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1493_CR58","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/jpc.12811","volume":"51","author":"AM Connolly","year":"2015","unstructured":"Connolly AM, Beavis E, Mugica-Cox B, Bye AM, Lawson JA. Exploring carer perceptions of training in out-of-hospital use of buccal midazolam for emergency management of seizures (2008\u20132012). J Paediatr Child Health. 2015;51(7):704\u20137. https:\/\/doi.org\/10.1111\/jpc.12811.","journal-title":"J Paediatr Child Health"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01493-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01493-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01493-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:05:31Z","timestamp":1764594331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01493-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1493"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01493-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MC has received research grants from Eisai and Angelini Pharma; fees for speaking and advisory boards from Biocodex, Arvelle, Neuraxpharm, UCB, Eisai, Jazz Pharmaceuticals, and Livanova; and fees for teaching activities from Angelini Pharma and UCB Pharma. IKN and MFF are full-time employees of Neuraxpharm. PM and CV are full-time employees of CTI Laboratory Services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MC: conceptualization, methodology, writing and original draft preparation, writing \u2013 review and editing. IKN and MFF: conceptualization, methodology, funding acquisition, writing \u2013 review & editing. PM and CV: methodology, writing \u2013 review & editing. All authors approved the final version for publication and agree to be accountable for the work presented.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}